For research use only. Not for therapeutic Use.
(R)-CR8 trihydrochloride（Cat No.:I017466）is a potent and selective cyclin-dependent kinase (CDK) inhibitor, particularly targeting CDK1, CDK2, CDK5, and CDK9. By inhibiting these CDKs, (R)-CR8 interferes with cell cycle progression and transcription regulation, leading to cell cycle arrest and apoptosis, especially in rapidly proliferating cancer cells. Its selectivity for CDKs makes it a valuable compound in cancer research, particularly for studying CDK-driven tumors and potential therapeutic interventions. (R)-CR8 trihydrochloride is also explored for its role in neurodegenerative diseases due to CDK involvement in neuronal cell death.
| Catalog Number | I017466 |
| CAS Number | 1786438-30-9 |
| Molecular Formula | C₂₄H₃₂Cl₃N₇O |
| Purity | ≥95% |
| Storage | Store at -20°C |
| IUPAC Name | (2R)-2-[[9-propan-2-yl-6-[(4-pyridin-2-ylphenyl)methylamino]purin-2-yl]amino]butan-1-ol;trihydrochloride |
| InChI | InChI=1S/C24H29N7O.3ClH/c1-4-19(14-32)28-24-29-22(21-23(30-24)31(15-27-21)16(2)3)26-13-17-8-10-18(11-9-17)20-7-5-6-12-25-20;;;/h5-12,15-16,19,32H,4,13-14H2,1-3H3,(H2,26,28,29,30);3*1H/t19-;;;/m1.../s1 |
| InChIKey | ORYSYXHQFOWNDK-RGFWRHHQSA-N |
| SMILES | CCC(CO)NC1=NC(=C2C(=N1)N(C=N2)C(C)C)NCC3=CC=C(C=C3)C4=CC=CC=N4.Cl.Cl.Cl |
| Reference | [1]. Bettayeb K, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene. 2008 Oct 2;27(44):5797-807.<br>[2]. Kabadi SV, et al. CR8, a novel inhibitor of CDK, limits microglial activation, astrocytosis, neuronal loss, and neurologic dysfunction after experimental traumatic brain injury. J Cereb Blood Flow Metab. 2014 Mar;34(3):502-13.<br>[3]. Słabicki M, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K [published online ahead of print, 2020 Jun 3]. Nature. 2020;10.1038/s41586-020-2374-x. |
